Similar articles for PMID: 22055210

Year	Number of Results
1999	1
2004	3
2005	4
2006	4
2007	11
2008	13
2009	36
2010	32
2011	52
2012	44
2013	40
2014	51
2015	55
2016	42
2017	25
2018	14
2019	12
2020	9
2021	6
2022	2

1

Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studies.

Bode BW, Brett J, Falahati A, Pratley RE. Bode BW, et al. Am J Geriatr Pharmacother. 2011 Dec;9(6):423-33. doi: 10.1016/j.amjopharm.2011.09.007. Epub 2011 Nov 4. Am J Geriatr Pharmacother. 2011. PMID: 22055210

2

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG. Moretto TJ, et al. Clin Ther. 2008 Aug;30(8):1448-60. doi: 10.1016/j.clinthera.2008.08.006. Clin Ther. 2008. PMID: 18803987 Clinical Trial.

3

A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.

Montanya E, Sesti G. Montanya E, et al. Clin Ther. 2009 Nov;31(11):2472-88. doi: 10.1016/j.clinthera.2009.11.034. Clin Ther. 2009. PMID: 20109994 Review.

4

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Nishida T, Kaku K. Seino Y, et al. Curr Med Res Opin. 2010 May;26(5):1013-22. doi: 10.1185/03007991003672551. Curr Med Res Opin. 2010. PMID: 20199137 Clinical Trial.

5

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Seino Y, et al. Diabetes Res Clin Pract. 2008 Aug;81(2):161-8. doi: 10.1016/j.diabres.2008.03.018. Epub 2008 May 20. Diabetes Res Clin Pract. 2008. PMID: 18495285 Clinical Trial.

6

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.

Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME. Barnett AH, et al. Clin Ther. 2007 Nov;29(11):2333-48. doi: 10.1016/j.clinthera.2007.11.006. Clin Ther. 2007. PMID: 18158075 Clinical Trial.

7

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor linagliptin: a 4-week multicenter, randomized, double-blind, placebo-controlled phase IIa study in Japanese type 2 diabetes patients.

Horie Y, Kanada S, Watada H, Sarashina A, Taniguchi A, Hayashi N, Graefe-Mody EU, Woerle HJ, Dugi KA. Horie Y, et al. Clin Ther. 2011 Jul;33(7):973-89. doi: 10.1016/j.clinthera.2011.06.005. Epub 2011 Jul 2. Clin Ther. 2011. PMID: 21723606 Clinical Trial.

8

Efficacy and safety profile of exenatide once weekly compared with insulin once daily in Japanese patients with type 2 diabetes treated with oral antidiabetes drug(s): results from a 26-week, randomized, open-label, parallel-group, multicenter, noninferiority study.

Inagaki N, Atsumi Y, Oura T, Saito H, Imaoka T. Inagaki N, et al. Clin Ther. 2012 Sep;34(9):1892-908.e1. doi: 10.1016/j.clinthera.2012.07.007. Epub 2012 Aug 9. Clin Ther. 2012. PMID: 22884767 Clinical Trial.

9

GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.

Esposito K, Mosca C, Brancario C, Chiodini P, Ceriello A, Giugliano D. Esposito K, et al. Curr Med Res Opin. 2011 Aug;27(8):1519-28. doi: 10.1185/03007995.2011.590127. Epub 2011 Jun 13. Curr Med Res Opin. 2011. PMID: 21663496

10

Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.

Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O; Liraglutide Dose-Response Study Group. Feinglos MN, et al. Diabet Med. 2005 Aug;22(8):1016-23. doi: 10.1111/j.1464-5491.2005.01567.x. Diabet Med. 2005. PMID: 16026367 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed